We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 1.32% | 7.70 | 7.60 | 7.80 | 7.70 | 7.65 | 7.70 | 701,634 | 10:19:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -3.93M | -0.0079 | -9.75 | 38M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/2/2024 15:35 | give him some credit, he always hits the head on the nail......... | staverton | |
15/2/2024 15:09 | I have no idea why some people need to resort to facts and accuracy to counter fantasy and delusion:-) | lfdkmp | |
15/2/2024 15:01 | Sickothetech TOTALLY lying again, the CEO at Hvivo hasn't sold any shares as they are tied up in his incentive plan. Stop spreading FUD and get back to that disaster over at TOTALLY. | muchodinero | |
15/2/2024 14:59 | You truly are a moron, nobody got HVO spectacularly wrong, it's still over double what it was since you started talking BS about it, TLY on the other hand you DID get spectacularly wrong and are clearly angry you missed out on HVO so you spend your time trying to spread completely inaccurate BS, then talk like you actually understand anything, which of course you don't. You honestly should consider getting some serious mental help, it's not healthy to be both an idiot and completely wrong all of the time | adzy89 | |
15/2/2024 14:37 | 1gw, LinkedIn again!!! No wonder you keep getting it wrong. Staff say anyone they want on LinkedIn. It's not official company announcement. You and your mates should trying being honest for once. You and your mates got HVO spectacularly wrong, just like virtually every other share. I said it was being talked up. The huge CEO options, CF's holding. Read and crucially, understand the company newsflow. On shares you ramp, you overplay the jam, underplay the risks. Polb mcap £50m, revenue NIL TLY mcap £10m, revenue £100m | sikhthetech | |
15/2/2024 14:28 | Ah, Sickothetech the TOTALLY (TLY) loser now appears on Poolbeg board, how's that 95% loss your nursing over a Totally useless doing? 😕 Beware of Sickothetech trying to trash your investment here with multiple ID'S. | muchodinero | |
15/2/2024 11:57 | Parsons4, "seems to me that CF is desperate to get the shares moving." Absolutely. As I predicted on HVO, company being talked up. They obviously want out sooner rather than later. The fact is as of latest AR, POLB has zero revenue. Jam tomorrow. Huge MCAP of £50m. A placing on the cards. | sikhthetech | |
15/2/2024 11:07 | parsons4 - well if we take CF's relatively recent linkedin post at face value (and I know some don't) about aiming to complete the IPO of POLB on Nasdaq later this year then I can understand his desire to get the share price up ahead of setting the price for that. If I were then to look at even more recent discussion of acquiring and commercialising rare/orphan disease drugs, I might start to think that there could be a plan to acquire or reverse in to an existing Nasdaq-quoted company that was low on cash but had some promising approved or late phase drugs, particularly if those drugs were in the oncology space that would fit with trials of POLB001 for immunotherapy-induce Whether IPO'ing directly as POLB, or raising cash following, or as part of, an acquisition/reverse, a high shareprice would be a lot more useful than a low shareprice in terms of minimising the dilution of existing shareholders. | 1gw | |
15/2/2024 10:05 | Surprised nobody has commented on (from today's RNS) : "... with vesting conditional upon the weighted-average of the mid-market closing price of the ordinary shares in the Company being 17.945 pence or above over a period of fourteen calendar days (representing a c.85% premium to the share price at close of market on February 14, 2024)." Maybe an indication of management's expectations of share price in medium term? (as it stands today, not exactly a gimme ) | lfdkmp | |
15/2/2024 09:38 | It seems to me that CF is desperate to get the shares moving. I wouldn't be surprised if there was some deal in the offing that would be better with a higher share price !!!!!! | parsons4 | |
15/2/2024 09:16 | Seen #POLB RNS "...I also intend to start increasing my shareholding in Poolbeg as and when I am able to do so..." Exec Chairman Cathal Friel https://www.londonst | burtond1 | |
15/2/2024 09:13 | It looks like full steam ahead on the Cathal express train following today's RNS here and yesterday's announcements over at Hvivo. Cathal standing on the foot plate and going to a very exiting destination we hope? | muchodinero | |
15/2/2024 08:58 | CF can't buy at moment so news due | master investor | |
15/2/2024 08:16 | So if Friel is giving himself more shares here he's hardly going to buy more. | chica1 | |
15/2/2024 08:05 | And if you have not then perhaps you have not seen the many comments from that poster undermining this company | inaminute | |
15/2/2024 08:04 | Have you just got your log ins mixed up? Looks like it and if so proves my point | inaminute | |
15/2/2024 08:00 | Not sure how this is good news. Skillington has just become Friel's lapdog | chica1 | |
15/2/2024 07:40 | That is because you are thick | inaminute | |
15/2/2024 07:37 | i dont ubderstand a thing in today's rns with regard to cathal's role | ali47fish | |
15/2/2024 07:36 | yes trout I think the co-ordinates have been fundamentally reprogrammed | lfdkmp | |
15/2/2024 07:33 | If this isn't the biggest clue yet, about where they believe POLB will go.... | troutisout | |
15/2/2024 07:30 | Hmmm.... moving to a smaller office down the corridor, Jeremy? | lfdkmp | |
14/2/2024 17:57 | 1gw, Yes the 10.5p was deleted and it was then put through at 9.9p | troutisout |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions